 |
|
The Short-term Effect of Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.
Hyoung Seok Kim, Jae Heung Lee
J Korean Ophthalmol Soc. 2010;51(6):860-864. Published online 2010 Jun 15 DOI: https://doi.org/10.3341/jkos.2010.51.6.860
|
|
Citations to this article as recorded by
 Efficacy of Intravitreal Bevacizumab for Recurrent Central Serous Chorioretinopathy in Patients Who Had Previously Responded Well to the Same Therapy
Kyung-Hoon Shin, Jae Hui Kim, Sung Won Cho, Tae Gon Lee, Chul Gu Kim, Jong Woo Kim
Journal of Ocular Pharmacology and Therapeutics.2016; 32(7): 425. CrossRef A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study
John D Pitcher, Andre J Witkin, Francis Char DeCroos, Allen C Ho
British Journal of Ophthalmology.2015; 99(6): 848. CrossRef Factors Influencing the Effect of the Intravitreal Bevacizumab Injection in Patients with Central Serous Chorioretinopathy
Eui Yong Kweon
Journal of the Korean Ophthalmological Society.2014; 55(3): 391. CrossRef Review and update of central serous chorioretinopathy
Alexander Ross, Adam H Ross, Quresh Mohamed
Current Opinion in Ophthalmology.2011; 22(3): 166. CrossRef
|